A recent study indicates that people who come off new slimming jabs like semaglutide or tirzepatide tend to recover lost weight far faster than those who end conventional diet and exercise regimens.
Findings released in a leading health publication demonstrates that while overweight people frequently drop a large proportion of their total mass while using the jabs, the weight is regained at an estimated rate of 0.8 kg per month once they quit.
"Individuals purchasing these treatments must be cognizant of the potential of quick weight regain when the therapy is stopped," cautioned expert Dr. Susan Jebb.
Such speed of regain implies a return to pre-treatment mass in about a year and a half.
Analyzing Approaches
The study, which looked at 37 of studies involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with other pills.
Researchers note that people who shed pounds through lifestyle changes alone typically experience a more gradual weight regain—approximately 100 grams monthly—after stopping.
Understanding the Fast Regain
Experts believe the mechanism of the drugs accounts for the heightened weight return.
GLP-1 drugs imitate a body's own chemical called GLP-1, which helps regulate appetite.
"Artificially providing GLP-1 levels several times higher than normal might result in the body to produce less of its own natural GLP-1, and may also reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication results in hunger is uncontrolled, making binge eating a significant risk."
A Lifelong Condition?
Health authorities recommend the jabs for individuals with obesity-related health risks, alongside prescribed lifestyle changes.
Many experts contend that, given the significant potential of relapse, the therapy should be considered life-long.
This opinion is reinforced by pharmaceutical companies, who say that the results "highlight the persistent character of obesity," akin to managing conditions like high blood pressure.
Patient Experiences
People who have come off the medication describe a sudden resurgence of cravings.
"It felt as if something that goes on and you're instantly extremely hungry," recalled one woman.
This difficulty is exacerbated if users have not developed lasting dietary or behavioural modifications during treatment.
Significant Use
Survey data indicate that a significant number of adults in the UK have used these injections in the past year, with demand continuing to grow.
- Adoption is higher among women compared to males.
- The middle-aged demographic shows the highest usage rates.
- Many obtain the medications through private prescriptions rather than public health services.
Ultimately, clinicians caution that while GLP-1 drugs are potent tools for weight loss, they are not a permanent fix and maintained weight loss relies on combined behavioural support.
